EquiPrEP: An implementation science protocol for promoting equitable access and uptake of long-acting injectable HIV pre-exposure prophylaxis (LAI-PrEP).
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
12
05
2023
accepted:
03
09
2023
medline:
21
9
2023
pubmed:
19
9
2023
entrez:
19
9
2023
Statut:
epublish
Résumé
Long-acting injectable HIV pre-exposure prophylaxis (LAI-PrEP) was approved by the U.S. Food and Drug Administration in December 2021. This initial phase of implementation represents a prime opportunity to ensure equitable LAI-PrEP provision to communities often underrepresented in PrEP care before disparities in access and uptake emerge. Herein, we describe the EquiPrEP Project which utilizes an equity-oriented implementation science framework to optimize LAI-PrEP rollout in an urban safety-net clinic in New York City. The primary objectives of this project are to: (1) increase LAI-PrEP initiation overall; (2) increase uptake among groups disproportionately impacted by the HIV epidemic; (3) preserve high PrEP retention while expanding use; and (4) identify barriers and facilitators to LAI-PrEP use. EquiPrEP will enroll 210 PrEP-eligible participants into LAI-PrEP care with planned follow-up for one year. We will recruit from the following priority populations: Black and/or Latine men who have sex with men, Black and/or Latine cisgender women, and transgender women and nonbinary individuals. To evaluate implementation of LAI-PrEP, we will utilize equity-focused iterations of the Reach, Effectiveness, Adoption, Implementation, Maintenance (RE-AIM) framework and the Consolidated Framework for Implementation Research (CFIR), in addition to longitudinal surveys and qualitative interviews. Novel LAI-PrEP formulations carry tremendous potential to revolutionize the field of HIV prevention. Implementation strategies rooted in equity are needed to ensure that marginalized populations have access to LAI-PrEP and to address the structural factors that hinder initiation and retention in care.
Sections du résumé
BACKGROUND
Long-acting injectable HIV pre-exposure prophylaxis (LAI-PrEP) was approved by the U.S. Food and Drug Administration in December 2021. This initial phase of implementation represents a prime opportunity to ensure equitable LAI-PrEP provision to communities often underrepresented in PrEP care before disparities in access and uptake emerge. Herein, we describe the EquiPrEP Project which utilizes an equity-oriented implementation science framework to optimize LAI-PrEP rollout in an urban safety-net clinic in New York City.
METHODS
The primary objectives of this project are to: (1) increase LAI-PrEP initiation overall; (2) increase uptake among groups disproportionately impacted by the HIV epidemic; (3) preserve high PrEP retention while expanding use; and (4) identify barriers and facilitators to LAI-PrEP use. EquiPrEP will enroll 210 PrEP-eligible participants into LAI-PrEP care with planned follow-up for one year. We will recruit from the following priority populations: Black and/or Latine men who have sex with men, Black and/or Latine cisgender women, and transgender women and nonbinary individuals. To evaluate implementation of LAI-PrEP, we will utilize equity-focused iterations of the Reach, Effectiveness, Adoption, Implementation, Maintenance (RE-AIM) framework and the Consolidated Framework for Implementation Research (CFIR), in addition to longitudinal surveys and qualitative interviews.
DISCUSSION
Novel LAI-PrEP formulations carry tremendous potential to revolutionize the field of HIV prevention. Implementation strategies rooted in equity are needed to ensure that marginalized populations have access to LAI-PrEP and to address the structural factors that hinder initiation and retention in care.
Identifiants
pubmed: 37725628
doi: 10.1371/journal.pone.0291657
pii: PONE-D-23-12682
pmc: PMC10508596
doi:
Types de publication
Journal Article
Research Support, U.S. Gov't, P.H.S.
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0291657Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR001445
Pays : United States
Informations de copyright
Copyright: © 2023 Kaul et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
AIDS Care. 2019 Oct;31(10):1234-1240
pubmed: 31043069
AIDS Behav. 2012 May;16(4):1075-83
pubmed: 21785873
J Acquir Immune Defic Syndr. 2018 Nov 1;79(3):323-329
pubmed: 30044303
J Acquir Immune Defic Syndr. 2022 Jul 1;90(S1):S235-S246
pubmed: 35703776
AIDS Educ Prev. 2018 Jun;30(3):243-253
pubmed: 29969308
J Urban Health. 2005 Jun;82(2 Suppl 2):ii3-12
pubmed: 15888635
Health Aff (Millwood). 2018 Feb;37(2):178-180
pubmed: 29401032
BMC Public Health. 2021 Nov 27;21(1):2174
pubmed: 34837988
AIDS Patient Care STDS. 2020 Jun;34(6):259-266
pubmed: 32484743
Implement Sci. 2018 Sep 4;13(1):118
pubmed: 30180860
PLoS One. 2022 Apr 15;17(4):e0267031
pubmed: 35427397
Curr Opin HIV AIDS. 2020 Mar;15(2):142-149
pubmed: 31895141
AIDS Behav. 2018 Apr;22(4):1184-1189
pubmed: 28913659
AIDS Care. 2021 Jun;33(6):706-711
pubmed: 32838546
N Engl J Med. 2021 Aug 12;385(7):595-608
pubmed: 34379922
Health Promot Pract. 2006 Jul;7(3):312-23
pubmed: 16760238
Implement Sci. 2009 Aug 07;4:50
pubmed: 19664226
Am J Public Health. 1999 Sep;89(9):1322-7
pubmed: 10474547
J Assoc Nurses AIDS Care. 2023 Jan-Feb 01;34(1):24-30
pubmed: 36511759
Curr Opin HIV AIDS. 2022 Jul 1;17(4):192-198
pubmed: 35762373
Top Antivir Med. 2018 Apr;25(4):138-142
pubmed: 29689539
Am J Public Health. 2010 Apr 1;100 Suppl 1:S30-5
pubmed: 20147679
Front Public Health. 2020 May 12;8:134
pubmed: 32478025
Ann Epidemiol. 2018 Dec;28(12):833-840
pubmed: 30037634
AIDS Behav. 2020 Sep;24(9):2520-2531
pubmed: 32052214
N Engl J Med. 2007 Nov 1;357(18):1834-40
pubmed: 17978292
Lancet HIV. 2020 Aug;7(8):e582-e592
pubmed: 32763221